Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control

Experimental and Molecular Medicine

Volumn 47, Issue 8, 2015, Pages

  Durai, Prasannavenkatesh ^a   Batool, Maria ^a   Shah, Masaud ^a   Choi, Sangdun ^a  

^a Ajou University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORONAVIRUS SPIKE GLYCOPROTEIN; DIPEPTIDYL PEPTIDASE IV;

ANIMAL; CELL LINE; CORONAVIRUS INFECTIONS; DRUG DEVELOPMENT; DRUG EFFECTS; EPIDEMIC; HOST PATHOGEN INTERACTION; HUMAN; METABOLISM; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CORONAVIRUS INFECTIONS; DIPEPTIDYL PEPTIDASE 4; DISEASE OUTBREAKS; DRUG DISCOVERY; HOST-PATHOGEN INTERACTIONS; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR TARGETED THERAPY; SPIKE GLYCOPROTEIN, CORONAVIRUS;

EID: 85016626167     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/EMM.2015.76     Document Type: Article

References (78)

1. Baez-Santos YM, Mielech AM, Deng X, Baker S, Mesecar AD. Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus. J Virol 2014; 88: 12511–12527.
2. Banik GR, Khandaker G, Rashid H. Middle East Respiratory Syndrome Coronavirus ‘MERS-CoV’: current knowledge gaps. Paediatr Respir Rev 2015; 16: 197–202.
3. Kayali G, Peiris M. A more detailed picture of the epidemiology of Middle East respiratory syndrome coronavirus. Lancet Infect Dis 2015; 15: 495–497.
4. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. NEnglJMed2012; 367: 1814–1820.
5. Milne-Price S, Miazgowicz KL, Munster VJ. The emergence of the Middle East respiratory syndrome coronavirus. Pathog Dis 2014; 71: 121–136.
6. Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coronavirus: transmission and phylogenetic evolution. Trends Microbiol 2014; 22: 573–579.
7. Woo PC, Lau SK, Chu CM, Chan KH, Tsoi HW, Huang Y et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 2005; 79: 884–895.
8. Kahn JS, McIntosh K. History and recent advances in coronavirus discovery. Pediatr Infect Dis J 2005; 24: S223–S227, discussion S226.
9. Lee H, Lei H, Santarsiero BD, Gatuz JL, Cao S, Rice AJ et al. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV. ACS Chem Biol 2015; 10: 1456–1465.
10. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 2009; 7: 439–450.
11. Raj VS, Osterhaus AD, Fouchier RA, Haagmans BL. MERS: emergence of a novel human coronavirus. Curr Opin Virol 2014; 5: 58–62.
12. Hocke AC, Becher A, Knepper J, Peter A, Holland G, Tonnies M et al. Emerging human middle East respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs. Am J Respir Crit Care Med 2013; 188: 882–886.
13. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015; doi:10.1016/S0140-6736(15)60454-8 (in press).
14. Watson JT, Hall AJ, Erdman DD, Swerdlow DL, Gerber SI. Unraveling the mysteries of Middle East respiratory syndrome coronavirus. Emerg Infect Dis 2014; 20: 1054–1056.
15. Rasmussen SA, Gerber SI, Swerdlow DL. Middle East respiratory syndrome coronavirus: update for clinicians. Clin Infect Dis 2015; 60: 1686–1689.
16. Zhang N, Jiang S, Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines 2014; 13: 761–774.
17. Tomar S, Johnston ML St, John SE, Osswald HL, Nyalapatla PR, Paul LN et al. Ligand-induced dimerization of MERS coronavirus nsp5 protease (3CLpro): implications for nsp5 regulation and the development of antivirals. JBiolChem2015; 290: 19403–19422.
18. Bailey-Elkin BA, Knaap RC, Johnson GG, Dalebout TJ, Ninaber DK, van Kasteren PB et al. Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression. J Biol Chem 2014; 289: 34667–34682.
19. Yang X, Chen X, Bian G, Tu J, Xing Y, Wang Y et al. Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease. J Gen Virol 2014; 95: 614–626.
20. Smith EC, Blanc H, Surdel MC, Vignuzzi M, Denison MR. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog 2013; 9: e1003565.
21. Xia S, Liu Q, Wang Q, Sun Z, Su S, Du L et al. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res 2014; 194: 200–210.
22. Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013; 500: 227–231.
23. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426: 450–454.
24. Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 2013; 11: 836–848.
25. Woo PC, Lau SK, Li KS, Tsang AK, Yuen KY. Genetic relatedness of the novel human group C betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5. Emerg Microbes Infect 2012; 1: e35.
26. Chan JF, Lau SK, Woo PC. The emerging novel Middle East respiratory syndrome coronavirus: the ‘knowns’ and ‘unknowns’. J Formos Med Assoc 2013; 112: 372–381.
27. Who Mers-Cov Research G, State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr 2013; 5: doi:10.1371/currents.outbreaks.0bf719e352e7478-f8ad85fa30127ddb8.
28. Jiang S, Lu L, Du L, Debnath AK. A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. JInfect2013; 66: 464–466.
29. Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495: 251–254.
30. Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 2005; 69: 635–664.
31. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol 2009; 7: 226–236.
32. Wang N, Shi X, Jiang L, Zhang S, Wang D, Tong P et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013; 23: 986–993.
33. Matsuyama S, Ujike M, Morikawa S, Tashiro M, Taguchi F. Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proc Natl Acad Sci USA 2005; 102: 12543–12547.
34. Sawicki SG, Sawicki DL, Siddell SG. A contemporary view of coronavirus transcription. J Virol 2007; 81: 20–29.
35. de Haan CA, Rottier PJ. Molecular interactions in the assembly of coronaviruses. Adv Virus Res 2005; 64: 165–230.
36. Balachandran S, Roberts PC, Brown LE, Truong H, Pattnaik AK, Archer DR et al. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 2000; 13: 129–141.
37. Kato H, Takahasi K, Fujita T. RIG-I-like receptors: cytoplasmic sensors for non-self RNA. Immunol Rev 2011; 243: 91–98.
38. Anwar MA, Basith S, Choi S. Negative regulatory approaches to the attenuation of Toll-like receptor signaling. Exp Mol Med 2013; 45: e11.
39. Krishnan J, Selvarajoo K, Tsuchiya M, Lee G, Choi S. Toll-like receptor signal transduction. Exp Mol Med 2007; 39: 421–438.
40. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413: 732–738.
41. Niemeyer D, Zillinger T, Muth D, Zielecki F, Horvath G, Suliman T et al. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. JVirol2013; 87: 12489–12495.
42. Siu KL, Yeung ML, Kok KH, Yuen KS, Kew C, Lui PY et al. Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response. J Virol 2014; 88: 4866–4876.
43. Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 2014; 5: 3067.
44. Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J et al. Pre-and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci USA 2015; 112: 8738–8743.
45. Agrawal AS, Garron T, Tao X, Peng BH, Wakamiya M, Chan TS et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 2015; 89: 3659–3670.
46. Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H et al. Protective efficacy of recombinant Modified Vaccinia virus Ankara (MVA) delivering Middle East respiratory syndrome coronavirus spike glycoprotein. JVirol 2015; 89: 8651–8656.
47. Bosch BJ, Raj VS, Haagmans BL. Spiking the MERS-coronavirus receptor. Cell Res 2013; 23: 1069–1070.
48. Raj VS, Smits SL, Provacia LB, van den Brand JM, Wiersma L, Ouwendijk WJ et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. J Virol 2014; 88: 1834–1838.
49. Ohnuma K, Haagmans BL, Hatano R, Raj VS, Mou H, Iwata S et al. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. J Virol 2013; 87: 13892–13899.
50. Al-Tawfiq JA, Memish ZA. What are our pharmacotherapeutic options for MERS-CoV? Expert Rev Clin Pharmacol 2014; 7: 235–238.
51. Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 2014; 111: 4970–4975.
52. Mielech AM, Kilianski A, Baez-Santos YM, Mesecar AD, Baker SC. MERS-CoV papain-like protease has deISGylating and deubiquitinating activities. Virology 2014; 450-451: 64–70.
53. Lin MH, Chuang SJ, Chen CC, Cheng SC, Cheng KW, Lin CH et al. Structural and functional characterization of MERS coronavirus papain-like protease. JBiomedSci2014; 21: 54.
54. Needle D, Lountos GT, Waugh DS. Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity. Acta Crystallogr D 2015; 71: 1102–1111.
55. Kilianski A, Mielech AM, Deng X, Baker SC. Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors. J Virol 2013; 87: 11955–11962.
56. Yang Y, Zhang L, Geng H, Deng Y, Huang B, Guo Y et al. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 2013; 4: 951–961.
57. de Haan CA, Masters PS, Shen X, Weiss S, Rottier PJ. The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host. Virology 2002; 296: 177–189.
58. Haijema BJ, Volders H, Rottier PJ. Live, attenuated coronavirus vaccines through the directed deletion of group-specific genes provide protection against feline infectious peritonitis. J Virol 2004; 78: 3863–3871.
59. Liu DX, Fung TS, Chong KK, Shukla A, Hilgenfeld R. Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Res 2014; 109: 97–109.
60. Levy DE, Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev 2001; 12: 143–156.
61. Matthews KL, Coleman CM, van der Meer Y, Snijder EJ, Frieman MB. The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling. J Gen Virol 2014; 95: 874–882.
62. Billiau A. Interferon: the pathways of discovery I. Molecular and cellular aspects. Cytokine Growth Factor Rev 2006; 17: 381–409.
63. Thompson AJ, Locarnini SA. Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response. Immunol Cell Biol 2007; 85: 435–445.
64. Fujita T, Onoguchi K, Onomoto K, Hirai R, Yoneyama M. Triggering antiviral response by RIG-I-related RNA helicases. Biochimie 2007; 89: 754–760.
65. Kowalinski E, Lunardi T, McCarthy AA, Louber J, Brunel J, Grigorov B et al. Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA. Cell 2011; 147: 423–435.
66. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. JInfect2013; 67: 606–616.
67. de Wilde AH, Raj VS, Oudshoorn D, Bestebroer TM, van Nieuwkoop S, Limpens RW et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment. J Gen Virol 2013; 94: 1749–1760.
68. Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2014; 95: 571–577.
69. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 2014; 58: 4885–4893.
70. Adedeji AO, Singh K, Kassim A, Coleman CM, Elliott R, Weiss SR et al. Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses. Antimicrob Agents Chemother 2014; 58: 4894–4898.
71. de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014; 58: 4875–4884.
72. Lundin A, Dijkman R, Bergstrom T, Kann N, Adamiak B, Hannoun C et al. Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus. PLoS Pathog 2014; 10: e1004166.
73. Surya W, Li Y, Verdia-Baguena C, Aguilella VM, Torres J. MERS coronavirus envelope protein has a single transmembrane domain that forms pentameric ion channels. Virus Res 2015; 201: 61–66.
74. Mackay IM, Arden KE. Middle East respiratory syndrome: an emerging coronavirus infection tracked by the crowd. Virus Res 2015; 202: 60–88.
75. Eckerle I, Muller MA, Kallies S, Gotthardt DN, Drosten C. In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East respiratory syndrome (MERS) Coronavirus infection. Virol J 2013; 10: 359.
76. Muller MA, Raj VS, Muth D, Meyer B, Kallies S, Smits SL et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio 2012; 3: e00515–00512.
77. Chan JF, Chan KH, Choi GK, To KK, Tse H, Cai JP et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis 2013; 207: 1743–1752.
78. Eckerle I, Corman VM, Muller MA, Lenk M, Ulrich RG, Drosten C. Replicative capacity of MERS coronavirus in livestock cell lines. Emerg Infect Dis 2014; 20: 276–279.